The Journal of Urology
Volume 170, Issue 3 , Pages 835-839, September 2003

Effectiveness Of Intravesical Resiniferatoxin For Anticholinergic Treatment Refractory Detrusor Overactivity Due To Nonspinal Cord Lesions

  • HANN-CHORNG KUO

      Affiliations

    • Corresponding Author InformationCorresponding author and requests for reprints: Department of Urology, Buddhist Tzu Chi General Hospital, 707, Sec. 3, Chung Yang Rd., Hualien, Taiwan (telephone: 886-3-8561825, ext. 2117; FAX: 886-3-8560794).

From the Department of Urology, Buddhist Tzu Chi General Hospital, Hualien, Taiwan

Accepted 14 March 2003.

ABSTRACT 

Purpose

Evidence suggests that unmyelinated C fibers become predominant in the mediation of the detrusor reflex in patients with chronic spinal cord lesions and possibly in idiopathic detrusor hyperactivity. Intravesical vanilloid therapy might be effective in treating refractory detrusor overactivity due to nonspinal cord lesion. This study investigated the clinical effect of intravesical resiniferatoxin in treating detrusor overactivity of nonspinal cord lesions refractory to anticholinergics.

Materials and Methods

A total of 41 patients received intravesical resiniferatoxin therapy with 10 ml of 100 nM resiniferatoxin in 10% ethanol solution for 40 minutes. The clinical effects on a decrease in incontinence episodes and urodynamic study were evaluated at baseline and after treatment. Clinical improvement was considered if patients became dry or had a decrease in incontinence episodes of 50%. Therapeutic results were analyzed by disease category and type of initial detrusor response.

Results

Of the 41 patients 10 had neurogenic lesions, 18 had previous transurethral prostatectomy and 13 had idiopathic detrusor overactivity. There were 20 women and 21 men with a mean age of 73.6 years (range 43 to 82) and a symptom duration of 3.6 ± 4.5 years. After resiniferatoxin treatment 21 patients had clinical improvement (51.2%) including 5 with neurogenic (50%), 11 with previous transurethral prostatectomy (61.1%) and 5 with idiopathic detrusor overactivity (38.5%). An improvement was found in 11 patients with type I initial response (84.6%), 3 patients with type II response (23%) and 7 patients with type III response (46.7%). The 21 patients with improvement had a significant increase in cystometric capacity (208 ± 80.7 vs 287.2 ± 118.6 ml, p = 0.001) and a significant decrease in detrusor pressure (33.6 ± 11.1 vs 27.4 ± 11.8 cmH2O, p = 0.047), but no significant difference in maximal flow rate and residual urine volume.

Conclusions

Intravesical resiniferatoxin was effective in treating refractory detrusor overactivity in 51.2% of patients with nonspinal cord lesions. Patients with detrusor overactivity due to previous bladder outlet obstruction benefited the most. Detrusor contractility decreased after resiniferatoxin treatment in the group with improvement but did not influence voiding efficiency. The initial detrusor response to resiniferatoxin treatment might predict the clinical outcome.

Key Words:  muscle contraction , nerve fibers, unmyelinated , administration, intravesical , capsaicin, bladder

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Editor’s Note: This article is the fifth of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 960 and 961.Study received institutional ethical and human subject protection committee approval.

PII: S0022-5347(05)63244-2

doi:10.1097/01.ju.0000081652.31524.27

The Journal of Urology
Volume 170, Issue 3 , Pages 835-839, September 2003